Cancer cells surviving cisplatin chemotherapy increase stress-induced OMA1 activity and mitochondrial fragmentation

M Melvin Li C Chenille A. McCullum L Louis T. A. Rolle Q Qin Ni (Institute for NanoBioTechnology) Z Zhuoxu Ge (Institute for NanoBioTechnology) S Sean X. Sun (Institute for NanoBioTechnology) K Kenneth J. Pienta (Urology, Oncology, Pharmacology and Molecular Sciences, and Chemical and Biomolecular Engineering Cancer Ecology Center at the Brady Urological Institute Johns Hopkins University Baltimore Maryland USA) S Sarah R. Amend (Urology and Oncology Cancer Ecology Center at the Brady Urological Institute Johns Hopkins School of Medicine Baltimore Maryland USA)

Abstract

Abstract Cancer is one of the leading causes of deaths worldwide. Once cancer cells acquire therapy resistance, they become the main driver of cancer lethality in patients. Thus, mechanisms of therapy resistance must be investigated to improve patient outcomes. Mitochondria are critical organelles in the cellular stress responses, undergoing dynamic morphological and functional changes in response to external stimuli. We and others have identified a chemotherapy-resistant cancer cell state where cells that survive treatment exhibit a dramatic increase in cell size and remain non-proliferative for weeks. In this study, we demonstrate that cancer cells that enter this resistant cell state in response to cisplatin increase OMA1 activity and decrease mitochondrial fusion and function to combat oxidative stress. These findings contribute to further understanding the role of the mitochondrial stress responses in therapy resistance in cancer and provide a potential therapeutic avenue to targeting cancer cells that enter this chemotherapy-resistant cell state.

Article Details

Volume / Issue Vol. 16, Issue 1
Published January 06, 2026
ISSN 2045-2322
Publisher Nature Portfolio

Journal Info

Scientific Reports

Nature Portfolio

ISSN: 2045-2322 Open Access Life Sciences

Authors (8)

M

Melvin Li

C

Chenille A. McCullum

L

Louis T. A. Rolle

Q

Qin Ni

Institute for NanoBioTechnology

Z

Zhuoxu Ge

Institute for NanoBioTechnology

S

Sean X. Sun

Institute for NanoBioTechnology

K

Kenneth J. Pienta

Urology, Oncology, Pharmacology and Molecular Sciences, and Chemical and Biomolecular Engineering Cancer Ecology Center at the Brady Urological Institute Johns Hopkins University Baltimore Maryland USA

S

Sarah R. Amend

Urology and Oncology Cancer Ecology Center at the Brady Urological Institute Johns Hopkins School of Medicine Baltimore Maryland USA